Niraparib as maintenance therapy for treating recurrent or primary-advanced endometrial cancer after chemotherapy in combination with dostarlimab.

Niraparib in combination with dostarlimab is in clinical development for patients with recurrent or primary-advanced endometrial cancer. Endometrial cancer occurs when cancer cells form in the tissues of the endometrium – the lining of the uterus. Symptoms may include irregular vaginal bleeding, painful urination, and pelvic pain. Advanced cancer means that the cancer has spread to other parts of the body; recurrent cancer means the cancer has come back after treatment. There is a need to develop new treatments and combinations that can produce longer-lasting positive outcomes for women with advanced/recurrent endometrial cancer.